💊 Viking Therapeutics Soars on Phase 3 Trial Progress, Gilead Gains on Positive HIV Treatment Data and BioMarin Climbs on FDA Approval | Biotech Sector Insights
Gilead Sciences Inc (GILD) saw a stock price increase after positive data release on Biktarvy at the AIDS 2024 Conference, while Sanofi's strong Q2 earnings and collaboration with Regeneron Pharmaceuticals Inc (REGN) on Dupixent drove REGN's market sentiment positively.
Welcome to the MarketReader Minute.
Below are AI-generated insights on moves in the health care/biotechnology sector, powered by MarketReader technology.
Thursday, July 25
IBB [+1.7%]
iShares Biotechnology ETF (IBB) increased by 1.5% today, coinciding with a 1.74% rise in the Russell 2000 Index. Top contributors to IBB's performance were GILD, REGN, AMGN, ARGX, and VRTX. Gilead Sciences Inc (GILD) saw a stock price increase after positive data release on Biktarvy at the AIDS 2024 Conference, while Sanofi's strong Q2 earnings and collaboration with Regeneron Pharmaceuticals Inc (REGN) on Dupixent drove REGN's market sentiment positively. Amgen Inc (AMGN) reached an all-time high reflecting positive investor sentiment, and Arxenx SE (ARGX) rose following surpassing Q2 earnings expectations and FDA label launch in CIDP.